Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,908.00GBp
10:44am EDT
Change (% chg)

-22.00 (-0.45%)
Prev Close
4,930.00
Open
4,963.00
Day's High
5,018.89
Day's Low
4,880.00
Volume
1,356,963
Avg. Vol
2,555,132
52-wk High
5,585.07
52-wk Low
3,996.00

Latest Key Developments (Source: Significant Developments)

Fibrogen announces receipt of $62 million license payment from Astrazeneca
Friday, 8 Jul 2016 04:00am EDT 

Fibrogen Inc : Fibrogen announces receipt of $62 million license payment from Astrazeneca .Astrazeneca,Co collaborating on development,commercialization of drug for treatment of Anemia in patients with CKD in U.S., China, other markets.  Full Article

Valeant Pharmaceuticals announces new licensing arrangement for Brodalumab in Europe
Friday, 1 Jul 2016 02:00am EDT 

Valeant Pharmaceuticals International Inc : Valeant Pharmaceuticals announces new licensing arrangement for Brodalumab in Europe . Says affiliate and Astrazeneca have amended Valeant's license for Brodalumab . Amendment for Brodalumab to terminate Valeant's right to develop and commercialize Brodalumab in Europe . Astrazeneca has entered into an agreement granting Leo Pharma exclusive rights to develop and commercialize Brodalumab in Europe . Under terms of amended agreement, Valeant will continue to hold license to develop and commercialize Brodalumab in U.S . As consideration for termination of European rights, Astrazeneca to pay to co an upfront payment and certain sales-based milestone payments .As consideration for termination of European rights, one of pre-launch milestones payable by co to Astrazeneca under original license reduced.  Full Article

U.S. FDA says continues to find benefits of flumist quadrivalent outweigh any potential risks
Tuesday, 28 Jun 2016 01:57pm EDT 

U.S. Food and Drug Administration (FDA): FDA continues to find that the benefits of flumist quadrivalent outweigh any potential risks . Agency has determined that specific regulatory action is not warranted at this time .Continues to work with medimmune to determine cause of lower than expected effectiveness of flumist quadrivalent observed in recent years.  Full Article

AstraZeneca says life sciences competitivess, drug access key after Brexit
Friday, 24 Jun 2016 02:00am EDT 

Astrazeneca Plc : Says would have been better for uk to remain in eu, will now be protracted period of transition . Astrazeneca says aims to safeguard competitiveness of life sciences industry and speed of patient access to innovative medicines Further company coverage: [AZN.L] (Reporting by UK bureau) ((uk.online@reuters.com;)).  Full Article

AstraZeneca confirms CDC interim recommendation on flu vaccine
Thursday, 23 Jun 2016 02:00am EDT 

Astrazeneca Plc :Confirmed that ACIP center of CDC has provided interim recommendation on use of flumist quadrivalent live attenuated influenza vaccine.  Full Article

Adherium says Astrazeneca will use its Smartinhaler platform in US clinical study
Monday, 13 Jun 2016 06:16pm EDT 

Adherium Ltd : Astrazeneca will use its smartinhalertm platform in US clinical study on patients with chronic obstructive pulmonary disease .  Full Article

EU health agency recommends approval of new hepatitis C drugs
Friday, 27 May 2016 07:21am EDT 

EU Medicines Agency : EU Medicines Agency recommendations for May 2016 . Recommends against approval of Takeda Pharmaceutical Co Ltd's <4502.T> ixazomib to treat multiple myeloma . Recommends approval of AstraZeneca Plc's saxagliptin/dapagliflozin to treat type 2 diabetes . Recommends approval of Takeda Pharmaceutical Co Ltd and Janssen's bortezomib to treat multiple myeloma . Recommends approval of Gilead Sciences Inc's sofosbuvir/velpatasvir to treat Hepatitis C .Recommends approval of Merck & Co's Elbasvir / grazoprevir to treat Hepatitis C.  Full Article

AstraZeneca announces positive results in breast cancer trial
Friday, 27 May 2016 02:03am EDT 

AstraZeneca Plc : Announced positive results from phase III falcon trial comparing faslodex 500mg (fulvestrant) to arimidex 1mg . Faslodex 500mg demonstrated superiority compared with arimidex 1mg in falcon; met primary endpoint of extended progression-free survival. . Full evaluation of data is ongoing and results are expected to be presented at a medical meeting in 2016. .Positive results from astrazeneca faslodex trial.  Full Article

AstraZeneca receives complete response letter from U.S. FDA for sodium zirconium cyclosilicate
Friday, 27 May 2016 02:00am EDT 

Astrazeneca Plc : Astrazeneca receives complete response letter from us fda for sodium zirconium cyclosilicate (zs-9) for oral suspension for treatment of hyperkalaemia . Co and zs pharma are evaluating content of CRL and will work closely with FDA to determine appropriate next steps for NDA . CRL refers to observations arising from a pre-approval manufacturing inspection . CRL does not require generation of new clinical data. . FDA also acknowledged receipt of recently-submitted data which it has yet to review .Interactions are ongoing with other health authorities in European Union and Australia, where sodium zirconium cyclosilicate is currently under separate regulatory review.  Full Article

AstraZeneca says launches and prices 2.2 bln euro of bonds
Monday, 9 May 2016 12:35pm EDT 

Astrazeneca Plc : Launch and pricing of eur2.2bn bond issues . Successful pricing of euro medium term notes in an aggregate principal amount of eur 2.2 billion consisting of three tranches .Proceeds of issues will be used for general corporate purposes, which may include repayment of debt.  Full Article

BRIEF-NewLink Genetics announces clinical collaboration with AstraZeneca​

* Newlink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer